Rhythm Pharmaceuticals director proposes $3.58M sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Rhythm Pharmaceuticals, Inc. director Lynn Tetrault reported a proposed sale of 37,000 common shares, with an aggregate market value of $3,581,230 and an approximate sale date of June 22, 2026. Tetrault acquired the shares from the issuer on June 22, 2026, through exercise of stock options with cash payment. The notice lists December 15, 2025, in the field for the plan adoption or instruction date if relying on Rule 10b5-1.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.